Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 4899-4906

  Lin, Hui Qiang ^a   Katsifis, Andrew ^a   Meriaty, Haider ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Drug sensitivity; Epidermal growth factor receptor; Gefitinib; Radiation

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; HUMANS; MELANOMA; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78751515206     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ciardiello F: Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60(Suppl 1): 25-32; discussion 41-22, 2000.
2. Ranson M: ZD1839 (Iressa™ ): for more than just non-small cell lung cancer. Oncologist 7(Suppl 4): 16-24, 2002.
3. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD, Jr., Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A and Pazdur R: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa™) tablets. Clin Cancer Res 10: 1212-1218, 2004.
4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003.
5. Le Tourneau C, Vidal L and Siu LL: Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist Updat 11: 99-109, 2008.
6. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T and Tamura T: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol 23: 6829-6837, 2005.
7. Song JY, Lee SW, Hong JP, Chang SE, Choe H and Choi J: Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. Cancer Lett 283: 135-142,2009.
8. Fairley JA, Baillie J, Bain M and Sinclair JH: Human cytomegalovirus infection inhibits epidermal growth factor (EGF) signalling by targeting EGF receptors. J Gen Virol 83: 2803-2810,2002.
9. Eicheler W, Krause M, Hessel F, Zips D and Baumann M: Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiother Oncol 76: 151-156, 2005.
10. Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB and Johnston PG: Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 5: 1154-1165, 2006.
11. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T and Kuwano M: Sensitivity to gefitinib (Iressa™, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signalregulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3: 465-472, 2004.
12. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J and Baselga J: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10: 6487-6501,2004.
13. Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A and Kudoh S: Gefitinib (Iressa™) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 6: 277, 2006.
14. Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326, 2003.
15. Coss RA, Leeper DB, Storck CW, Burd RM, Wachsberger PR and Dicker AP: The epidermal growth factor receptor inhibitor gefitinib (Iressa™ , ZD 1839) sensitizes human melanoma cells to hyperthermia. Int J Radiat Oncol Biol Phys 57: S352, 2003.
16. de Wit PE, Moretti S, Koenders PG, Weterman MA, van Muijen GN, Gianotti B and Ruiter DJ: Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 99: 168-173, 1992.
17. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D and Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987, 2003.
18. Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC, Calvo KR, Van Waes C and Chen Z: Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 15: 2361-2372, 2009.
19. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Baron A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J and Bunn PA Jr.: Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa™) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 12:7117-7125, 2006.
20. Schmidt-Ullrich RK, Valerie K, Fogleman PB and Walters J: Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145: 81-85, 1996.
21. Kraehn G, Greulich K, Schartl M, Kind P and Peter RU: Effect of ionizing radiation on receptor tyrosine kinases and p 16 expression in human malignant melanoma cell lines. Int J Radiat Oncol Biol Phys 36(Suppl 1): 371, 1996.
22. Harris RC, Chung E and Coffey RJ: EGF receptor ligands. Exp Cell Res 254: 2-13, 2003.
23. l24I-Iabeled small molecular tracer and positron-emission tomography. Mol Imaging Biol 8: 262-277, 2006.
24. Shokeen M and Anderson CJ: Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Ace Chem Res 42: 832-841, 2009.
25. Haedo W, Gonzalez T, Mas JA, Franco S, Gra B, Soto G, Alonso A and Lopez-Saura P: Oral human recombinant epidermal growth factor in the treatment of patients with duodenal ulcer. Rev Esp Enferm Dig 55: 409-418, 1996.
26. Itoh M and Matsuo Y: Gastric ulcer treatment with intravenous human epidermal growth factor: a double-blind controlled clinical study. J Gastroenterol Hepatol 9(Suppl 1): S78-83, 1994.
27. Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11: 689-708, 2004.
28. Gerber DE: EGFR inhibition in the treatment of non-small cell lung cancer. Drug Dev Res 69: 359-372, 2008.
29. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R and Elenius K: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12: 4103-4111, 2006.